|
gptkbp:instance_of
|
gptkb:physicist
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:VHL
|
|
gptkbp:associated_with
|
gptkb:hemangioblastomas
gptkb:healthcare_organization
gptkb:pheochromocytomas
|
|
gptkbp:caused_by
|
tumors
|
|
gptkbp:complications
|
gptkb:healthcare_organization
neurological issues
organ dysfunction
|
|
gptkbp:current_use
|
gptkb:neurofibromatosis_type_2
gptkb:Birt-Hogg-Dubé_syndrome
hereditary leiomyomatosis
|
|
gptkbp:descendant
|
autosomal dominant inheritance
|
|
gptkbp:discovered_by
|
gptkb:Arvid_Carlsson
|
|
gptkbp:first_described_by
|
1926
|
|
gptkbp:genetic_diversity
|
gptkb:stock_market_index
carrier testing
confirmatory test
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Von Hippel-Lindau syndrome
|
|
gptkbp:is_associated_with
|
gptkb:VHL_gene
|
|
gptkbp:is_popular_in
|
1 in 36,000
|
|
gptkbp:location
|
3p25.3
|
|
gptkbp:notable_event
|
gptkb:celebrities
public figures
notable individuals
|
|
gptkbp:public_awareness
|
gptkb:charity
social media campaigns
public health initiatives
|
|
gptkbp:research_focus
|
gptkb:physicist
clinical trials
targeted therapy
|
|
gptkbp:risk_factor
|
family history
mutation in VHL gene
|
|
gptkbp:scholarships
|
gptkb:Educational_Institution
counseling services
support groups
|
|
gptkbp:screenings
|
urine tests
blood pressure monitoring
regular imaging tests
|
|
gptkbp:social_responsibility
|
genetic testing
|
|
gptkbp:symptoms
|
dizziness
vision problems
headaches
|
|
gptkbp:treatment
|
gptkb:hospital
gptkb:drug
surveillance
|